Clinical trials: Metastasis
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)
This is medical research evaluating the safety and efficacy of two new medicines (necitumumab and abemaciclib), administered in combination in participants affected by a defined type of advanced lung cancer (stage IV…
- Trial name
- NCT02411591
- Testing
- Necitumumab, Abemaciclib
- Where
- 15 sites in Belgium, France and 1 more
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
Metastatic Leiomyosarcoma, Metastatic Liposarcoma
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
This phase I/II studies the side effects of avelumab and trabectedin and how well they work in treating patients with leiomyosarcoma or liposarcoma that has spread to other places in the body (metastatic) or cannot be removed by…
- Conditions
- Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma
- Trial name
- NCT03074318
- Testing
- Avelumab, Trabectedin
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Fred Hutchinson Cancer Center
Sarcoma
NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy
This pilot, phase I trial studies the safety of cancer-testis antigen (NY-ESO-1)-specific T cells (a type of immune cell) in treating patients with NY-ESO-1-expressing sarcomas that have spread to other places in the body and are…
- Trial name
- NCT02319824
- Testing
- Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Laboratory Biomarker Analysis, Palliative Radiation Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Fred Hutchinson Cancer Center
Neoplasm, Unknown Primary
Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site
We will evaluate the feasibility, toxicity, and effectiveness of combination chemotherapy (paclitaxel/carboplatin)plus combination targeted therapy (bevacizumab/erlotinib)in the first line treatment of patients with carcinoma of…
- Trial name
- NCT00360360
- Testing
- paclitaxel, carboplatin, bevacizumab
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- SCRI Development Innovations, LLC
Gastrointestinal Neoplasms, Ovarian Neoplasms
Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)
The purposes of this study are: 1. To assess the maximum tolerated dose of low-dose UART(Upper Abdominal Radiation Therapy ) or WART(Whole Abdominal Radiation Therapy) given in combination with standard fixed dose-rate…
- Trial name
- GCC0319 (NCT00390182)
- Testing
- Gemcitabine
- Where
- 2 sites in United States, Canada
- Volunteers
- 38 people
- Sponsor
- University of Maryland, Baltimore
Gastric Cancer
Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as floxuridine, leucovorin, oxaliplatin, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00448682
- Testing
- Docetaxel, Floxuridine, Leucovorin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Miami
Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
The purpose of this study is evaluate the efficacy and safety of FOLFIRINOX in patients with gastroenteropancreatic high-grade neuroendocrine carcinomas.
- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer, Neuroendocrine Carcinomas of Pancreas, Islet Cell Carcinoma
- Trial name
- NCT03042780
- Testing
- FOLFIRINOX, Granulocyte colony-stimulating factor (G-CSF)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Renal Cell Carcinoma
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following…
- Trial name
- IMmotion010 (NCT03024996)
- Testing
- Atezolizumab
- Where
- 186 sites in United States, Argentina and 26 more
- Volunteers
- 778 people
- Sponsor
- Hoffmann-La Roche
Amyloidosis
Safety and Effect of Doxycycline in Patients With Amyloidosis
The tetracycline antibiotic doxycycline disrupts A beta amyloid fibrils (AB) in Alzheimer's disease, transthyretin (ATTR) amyloid fibrils in familial amyloidotic polyneuropathy, and immunoglobulin light chain (AL) amyloid fibrils…
- Trial name
- NCT01677286
- Testing
- Doxycycline 100 mg po bid x 12 months
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Boston University
Cholangiocarcinoma
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
The purpose of this study is evaluate the efficacy of pemigatinib in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.
- Trial name
- NCT02924376
- Testing
- Pemigatinib
- Where
- 120 sites in United States, Belgium and 10 more
- Volunteers
- 147 people
- Sponsor
- Incyte Corporation
Metastatic Castration-resistant Prostate Cancer
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant…
- Trial name
- NCT03732820
- Testing
- olaparib, abiraterone acetate
- Where
- 132 sites in United States, Australia and 15 more
- Volunteers
- 895 people
- Sponsor
- AstraZeneca
Renal Cell Carcinoma
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
The purpose of this study is to see how well the study drug, axitinib, helps control renal (kidney) cancer that has come back (recurrent) or spread (metastatic).
- Trial name
- PrE0801 (NCT01649180)
- Testing
- Axitinib
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- PrECOG, LLC.
Neoplasms
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06664178 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02122146
- Testing
- PF-06664178
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Pfizer
Head and Neck Cancer
A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer
The purpose of this study is to determine the effectiveness and side effects of a new combination and schedule of chemotherapy drugs in the treatment of head and neck cancer.
- Trial name
- NCT00148122
- Testing
- Docetaxel, Capecitabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan Rogel Cancer Center
Chronic Kidney Disease
A Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease
Chronic kidney disease (CKD) is a major public health problem with a UK prevalence of 8-10%. The study hypothesis is to ascertain if intensive primary care led disease management programmes for CKD, supported by input from…
- Trial name
- NCT01688141
- Testing
- Enhanced management
- Where
- 3 sites in United Kingdom
- Volunteers
- 28,304 people
- Sponsor
- University Hospitals, Leicester
Melanoma
An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma
Cancers develop in two different ways. First, cancer cells can become invisible to the immune system by stop having proteins on their surface that are required for the immune system to recognize them.
- Trial name
- NCT03765229
- Testing
- Entinostat, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
This phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with anal canal cancer that has not responded to previous treatment (refractory) and that has spread from where it first started…
- Conditions
- Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Stage IV Anal Cancer AJCC v8
- Trial name
- NCT02314169
- Testing
- Biospecimen Collection, Computed Tomography, Ipilimumab
- Where
- 56 sites in United States, Canada
- Volunteers
- 143 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer
A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
This open-label, multi-center study will evaluate the efficacy and safety of Herceptin (trastuzumab) in combination with standard chemotherapy as first-line treatment in patients with HER2 positive metastatic adenocarcinoma of…
- Trial name
- NCT01260194
- Testing
- trastuzumab [Herceptin]
- Where
- 6 sites in India
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
Neoplasms
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors
This open-label, multicenter, Phase Ib dose-escalation study will evaluate the safety, tolerability and pharmacokinetics of oral dosing of GDC-0973 and GDC-0068 administered in combination in patients with locally advanced or…
- Trial name
- NCT01562275
- Testing
- Ipatasertib, Cobimetinib
- Where
- 5 sites in United States, Spain
- Volunteers
- 67 people
- Sponsor
- Genentech, Inc.
Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma
This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with…
- Trial name
- NCT02340975
- Testing
- MEDI4736 + tremelimumab, MEDI4736, Tremelimumab
- Where
- 28 sites in United States, Canada and 4 more
- Volunteers
- 114 people
- Sponsor
- MedImmune LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.